查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1951763

合约开发和生产组织 (CDMO) 市场分析及至 2035 年预测：按类型、产品、服务、技术、应用、最终用户、材料类型、阶段、工艺和实施类型划分

Contract Development and Manufacturing Organization (CDMO) Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Material Type, Stage, Process, Deployment
出版日期: | 出版商: Global Insight Services | 英文 312 Pages | 商品交期: 3-5个工作天内

价格
简介目录

合约研发生产机构（CDMO）市场预计将从2024年的1,600亿美元成长到2034年的3,150亿美元，复合年增长率约为6.7%。 CDMO市场涵盖为製药和生物技术公司提供从药物研发到生产的全方位服务的营业单位。 CDMO在製剂设计、製程开发和大规模生产方面拥有丰富的专业知识。该市场的成长动力来自外包趋势、对成本效益的需求以及对专业化生产能力的需求，以促进创新并加快药物上市速度。

受製药生产外包日益增长的推动，合约研发生产机构 (CDMO) 市场持续稳定扩张。按服务细分，生物製药的成长速度最快，这主要得益于市场对复杂生物製药和生物相似药的强劲需求。小分子药物紧随其后，在广泛的治疗应用领域保持着重要地位。在各个子细分领域中，原料原料药)服务占据主导地位，这主要得益于生物製药生产所需的复杂製程。製剂服务位居第二，反映出市场对製剂开发和包装解决方案的需求不断增长。个人化医疗和先进治疗方法的兴起进一步推动了对专业 CDMO 服务的需求。一次性技术和连续生产等技术进步对于优化生产效率至关重要。策略伙伴关係和合作的重要性日益凸显，使企业能够利用互补的专业知识并扩展其服务范围。随着监管要求的不断变化，CDMO 在确保合规性和加快产品上市速度方面仍然发挥着至关重要的作用。

市场区隔
类型 小分子药物、生物製药和先进治疗药物（ATMP）
产品 原料药（API）、成品剂型（FDF）、中间体
服务 製程开发、分析服务、製造、包装、法规支援、供应链管理
科技 生物製程、製剂、冷冻干燥、连续生产
适应症 肿瘤学、心血管疾病、神经学、感染疾病、免疫学、呼吸系统疾病
最终用户 製药公司、生技公司和研究机构
材料类型 合成的、生物的
步 临床前、临床、商业化
过程 发酵、化学合成、细胞培养
部署 内部、外包

合约开发与生产组织 (CDMO) 市场的特征是市场占有率分布多元化、定价策略多样，以及新产品层出不穷。该行业的成长主要得益于製药和生物技术行业对外包需求的不断增长。各公司正利用创新技术提升产品和服务，以实现更具竞争力的价格和更优质的服务。策略联盟和合作日益增多，促进了新产品和服务的推出。快速变化的客户需求和技术进步进一步凸显了市场的动态性。竞争标竿分析显示，市场竞争异常激烈，主要企业在追求卓越营运和市场差异化。监管影响至关重要，严格的合规要求塑造企业的策略。儘管市场由少数主要企业主导，但新兴企业也迅速崛起。北美和欧洲等地区的法规结构对于制定行业标准至关重要。在技​​术创新和对个人化医疗日益增长的关注的推动下，CDMO 市场预计将保持强劲成长。此外，企业还需应对复杂的法规环境并维持高标准的质量，这进一步加剧了竞争格局的复杂性。

主要趋势和驱动因素：

受几项关键趋势和驱动因素的影响，合约研发生产机构 (CDMO) 市场正经历强劲成长。首先，生物製药和生物相似药的需求不断增长，这是一个显着的趋势。随着製药公司专注于创新治疗方法，它们越来越多地转向 CDMO 来管理复杂的生产流程，从而推动了市场成长。其次，製药公司正在加速外包。透过利用 CDMO 的专业知识，这些公司可以缩短产品上市时间，并专注于自身的核心竞争力。这一趋势在寻求成本效益解决方案的中小型企业中尤其明显。第三，生产流程的技术进步正在改变 CDMO 的格局。连续生产和一次性使用技术等创新提高了效率和柔软性，吸引了更多客户选择 CDMO。此外，个人化医疗的兴起也推动了专业化生产能力的需求。最后，复杂的监管环境和严格的品质标准迫使製药公司与 CDMO 合作。这些机构拥有必要的认证和专业知识，能够应对监管环境，确保合规性并维持产品品质。这趋势凸显了CDMO在医药供应链中的战略重要性。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 小分子药物
    • 生物製药
    • 先进疗法药物（ATMP）
  • 市场规模及预测：依产品划分
    • 原料药（API）
    • 最终剂型（FDF）
    • 中级
  • 市场规模及预测：依服务划分
    • 製程开发
    • 分析服务
    • 製造业
    • 包装
    • 监管支持
    • 供应链管理
  • 市场规模及预测：依技术划分
    • 生物製程
    • 配方
    • 冷冻干燥
    • 连续製造
  • 市场规模及预测：依应用领域划分
    • 肿瘤学
    • 心血管疾病
    • 神经病学
    • 感染疾病
    • 免疫学
    • 呼吸系统疾病
  • 市场规模及预测：依最终用户划分
    • 製药公司
    • 生技公司
    • 研究所
  • 市场规模及预测：依材料类型划分
    • 合成
    • 生物製药
  • 市场规模及预测：依发展阶段划分
    • 临床前阶段
    • 临床
    • 商业的
  • 市场规模及预测：依製程划分
    • 发酵
    • 化学合成
    • 细胞培养
  • 市场规模及预测：依发展状况
    • 内部开发
    • 外包

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Catalent
  • Lonza Group
  • Recipharm
  • Siegfried Holding
  • Wu Xi App Tec
  • Samsung Biologics
  • Fujifilm Diosynth Biotechnologies
  • Boehringer Ingelheim Bio Xcellence
  • Patheon
  • Corden Pharma
  • Ajinomoto Bio-Pharma Services
  • Alcami Corporation
  • Piramal Pharma Solutions
  • Jubilant Hollister Stier
  • Cambrex Corporation
  • AMRI Global
  • Thermo Fisher Scientific
  • Vetter Pharma International
  • PCI Pharma Services
  • LSNE Contract Manufacturing

第九章：关于我们

简介目录
Product Code: GIS21685

Contract Development and Manufacturing Organization (CDMO) Market is anticipated to expand from $160 billion in 2024 to $315 billion by 2034, growing at a CAGR of approximately 6.7%. The Contract Development and Manufacturing Organization (CDMO) Market encompasses entities providing comprehensive services from drug development to manufacturing for pharmaceutical and biotech firms. CDMOs offer expertise in formulation, process development, and large-scale production. The market is propelled by increasing outsourcing trends, cost-efficiency demands, and the need for specialized manufacturing capabilities, fostering innovation and accelerating drug time-to-market.

The Contract Development and Manufacturing Organization (CDMO) market is experiencing robust expansion, propelled by the increasing outsourcing of pharmaceutical manufacturing. Within the service segments, the biologics segment outperforms, driven by the surge in demand for complex biologic drugs and biosimilars. The small molecule segment follows, maintaining significance due to its broad therapeutic applications. In the sub-segments, drug substance services lead, fueled by the intricate processes required for biologic drug production. Drug product services are the second highest-performing sub-segment, reflecting the growing need for formulation development and packaging solutions. The rise of personalized medicine and advanced therapies further enhances the demand for specialized CDMO services. Technological advancements, such as single-use technologies and continuous manufacturing, are pivotal in optimizing production efficiency. Strategic partnerships and collaborations are becoming increasingly vital, enabling companies to leverage complementary expertise and expand their service offerings. As regulatory requirements evolve, CDMOs remain critical in ensuring compliance and accelerating time-to-market.

Market Segmentation
TypeSmall Molecule, Biologics, Advanced Therapy Medicinal Products (ATMPs)
ProductActive Pharmaceutical Ingredients (APIs), Finished Dosage Forms (FDFs), Intermediates
ServicesProcess Development, Analytical Services, Manufacturing, Packaging, Regulatory Support, Supply Chain Management
TechnologyBioprocessing, Formulation, Lyophilization, Continuous Manufacturing
ApplicationOncology, Cardiovascular Diseases, Neurology, Infectious Diseases, Immunology, Respiratory Diseases
End UserPharmaceutical Companies, Biotechnology Companies, Research Institutes
Material TypeSynthetic, Biological
StagePreclinical, Clinical, Commercial
ProcessFermentation, Chemical Synthesis, Cell Culture
DeploymentIn-house, Outsourced

The Contract Development and Manufacturing Organization (CDMO) market is characterized by a diverse landscape of market share distribution, pricing strategies, and a continuous stream of new product launches. The sector's growth is propelled by the increasing demand for outsourcing in pharmaceutical and biotechnology industries. Companies are leveraging innovative technologies to enhance their offerings, leading to competitive pricing and improved service delivery. The market is witnessing a surge in strategic partnerships and collaborations, which are fostering the introduction of novel products and services. The dynamic nature of this market is further accentuated by the rapid evolution of customer needs and technological advancements. Competition benchmarking reveals a highly competitive environment with key players striving to achieve operational excellence and market differentiation. Regulatory influences play a pivotal role, with stringent compliance requirements shaping operational strategies. The market is dominated by a few major players, yet emerging companies are making significant inroads. Regulatory frameworks in regions such as North America and Europe are pivotal in setting industry standards. The CDMO market is poised for robust growth, driven by technological innovations and an increasing focus on personalized medicine. The competitive landscape is further complicated by the need to navigate complex regulatory environments and maintain high-quality standards.

Geographical Overview:

The Contract Development and Manufacturing Organization (CDMO) market is witnessing robust growth across various regions, each presenting unique opportunities. North America remains a dominant force, driven by advanced pharmaceutical innovations and significant investment in biotechnology. The presence of key industry players and a strong regulatory framework further bolster the market's expansion. Europe is experiencing substantial growth, fueled by increased demand for biologics and personalized medicine. The region's focus on sustainable manufacturing practices enhances its competitive edge. In the Asia Pacific, rapid industrialization and a burgeoning middle class are propelling market growth. Countries like China and India are emerging as pivotal players due to their expanding pharmaceutical sectors and cost-effective manufacturing capabilities. Latin America and the Middle East & Africa are also gaining traction. In Latin America, improving healthcare infrastructure and rising investments in pharmaceutical research are driving growth. Meanwhile, the Middle East & Africa are recognizing the potential of CDMOs in fostering economic diversification and innovation.

The CDMO market is increasingly influenced by global tariffs, geopolitical tensions, and evolving supply chain dynamics. In Japan and South Korea, trade tensions with the US and China are prompting investments in local biopharmaceutical capabilities to mitigate reliance on foreign entities. China, facing heightened scrutiny and export controls, is accelerating its domestic CDMO infrastructure to support its burgeoning pharmaceutical sector. Taiwan remains pivotal in the CDMO landscape, yet is vulnerable to geopolitical risks, especially concerning cross-strait relations. Globally, the CDMO market is robust, driven by rising demand for biologics and personalized medicine. By 2035, the market's evolution will hinge on strategic regional partnerships and supply chain resilience. Middle East conflicts could disrupt global supply chains, affecting energy prices and operational costs, thus influencing CDMO market strategies.

Key Trends and Drivers:

The Contract Development and Manufacturing Organization (CDMO) market is experiencing robust growth due to several critical trends and drivers. Firstly, the increasing demand for biologics and biosimilars is a significant trend. As pharmaceutical companies focus on innovative therapies, they are turning to CDMOs to manage complex manufacturing processes, thus driving market growth. Secondly, the trend towards outsourcing by pharmaceutical companies is accelerating. By leveraging CDMO expertise, these companies can reduce time to market and focus on core competencies. This trend is particularly prominent among small and medium-sized enterprises seeking cost-effective solutions. Thirdly, technological advancements in manufacturing processes are transforming the CDMO landscape. Innovations such as continuous manufacturing and single-use technologies are enhancing efficiency and flexibility, attracting more clients to CDMOs. Additionally, the rise of personalized medicine is driving demand for specialized manufacturing capabilities. Finally, regulatory complexities and stringent quality standards are compelling pharmaceutical companies to collaborate with CDMOs. These organizations possess the necessary certifications and expertise to navigate regulatory landscapes, ensuring compliance and maintaining product quality. This trend underscores the strategic importance of CDMOs in the pharmaceutical supply chain.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Material Type
  • 2.8 Key Market Highlights by Stage
  • 2.9 Key Market Highlights by Process
  • 2.10 Key Market Highlights by Deployment

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Small Molecule
    • 4.1.2 Biologics
    • 4.1.3 Advanced Therapy Medicinal Products (ATMPs)
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Active Pharmaceutical Ingredients (APIs)
    • 4.2.2 Finished Dosage Forms (FDFs)
    • 4.2.3 Intermediates
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Process Development
    • 4.3.2 Analytical Services
    • 4.3.3 Manufacturing
    • 4.3.4 Packaging
    • 4.3.5 Regulatory Support
    • 4.3.6 Supply Chain Management
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Bioprocessing
    • 4.4.2 Formulation
    • 4.4.3 Lyophilization
    • 4.4.4 Continuous Manufacturing
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Cardiovascular Diseases
    • 4.5.3 Neurology
    • 4.5.4 Infectious Diseases
    • 4.5.5 Immunology
    • 4.5.6 Respiratory Diseases
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Pharmaceutical Companies
    • 4.6.2 Biotechnology Companies
    • 4.6.3 Research Institutes
  • 4.7 Market Size & Forecast by Material Type (2020-2035)
    • 4.7.1 Synthetic
    • 4.7.2 Biological
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Preclinical
    • 4.8.2 Clinical
    • 4.8.3 Commercial
  • 4.9 Market Size & Forecast by Process (2020-2035)
    • 4.9.1 Fermentation
    • 4.9.2 Chemical Synthesis
    • 4.9.3 Cell Culture
  • 4.10 Market Size & Forecast by Deployment (2020-2035)
    • 4.10.1 In-house
    • 4.10.2 Outsourced

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Material Type
      • 5.2.1.8 Stage
      • 5.2.1.9 Process
      • 5.2.1.10 Deployment
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Material Type
      • 5.2.2.8 Stage
      • 5.2.2.9 Process
      • 5.2.2.10 Deployment
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Material Type
      • 5.2.3.8 Stage
      • 5.2.3.9 Process
      • 5.2.3.10 Deployment
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Material Type
      • 5.3.1.8 Stage
      • 5.3.1.9 Process
      • 5.3.1.10 Deployment
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Material Type
      • 5.3.2.8 Stage
      • 5.3.2.9 Process
      • 5.3.2.10 Deployment
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Material Type
      • 5.3.3.8 Stage
      • 5.3.3.9 Process
      • 5.3.3.10 Deployment
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Material Type
      • 5.4.1.8 Stage
      • 5.4.1.9 Process
      • 5.4.1.10 Deployment
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Material Type
      • 5.4.2.8 Stage
      • 5.4.2.9 Process
      • 5.4.2.10 Deployment
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Material Type
      • 5.4.3.8 Stage
      • 5.4.3.9 Process
      • 5.4.3.10 Deployment
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Material Type
      • 5.4.4.8 Stage
      • 5.4.4.9 Process
      • 5.4.4.10 Deployment
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Material Type
      • 5.4.5.8 Stage
      • 5.4.5.9 Process
      • 5.4.5.10 Deployment
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Material Type
      • 5.4.6.8 Stage
      • 5.4.6.9 Process
      • 5.4.6.10 Deployment
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Material Type
      • 5.4.7.8 Stage
      • 5.4.7.9 Process
      • 5.4.7.10 Deployment
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Material Type
      • 5.5.1.8 Stage
      • 5.5.1.9 Process
      • 5.5.1.10 Deployment
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Material Type
      • 5.5.2.8 Stage
      • 5.5.2.9 Process
      • 5.5.2.10 Deployment
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Material Type
      • 5.5.3.8 Stage
      • 5.5.3.9 Process
      • 5.5.3.10 Deployment
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Material Type
      • 5.5.4.8 Stage
      • 5.5.4.9 Process
      • 5.5.4.10 Deployment
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Material Type
      • 5.5.5.8 Stage
      • 5.5.5.9 Process
      • 5.5.5.10 Deployment
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Material Type
      • 5.5.6.8 Stage
      • 5.5.6.9 Process
      • 5.5.6.10 Deployment
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Material Type
      • 5.6.1.8 Stage
      • 5.6.1.9 Process
      • 5.6.1.10 Deployment
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Material Type
      • 5.6.2.8 Stage
      • 5.6.2.9 Process
      • 5.6.2.10 Deployment
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Material Type
      • 5.6.3.8 Stage
      • 5.6.3.9 Process
      • 5.6.3.10 Deployment
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Material Type
      • 5.6.4.8 Stage
      • 5.6.4.9 Process
      • 5.6.4.10 Deployment
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Material Type
      • 5.6.5.8 Stage
      • 5.6.5.9 Process
      • 5.6.5.10 Deployment

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Catalent
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Lonza Group
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Recipharm
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Siegfried Holding
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Wu Xi App Tec
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Samsung Biologics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Fujifilm Diosynth Biotechnologies
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Boehringer Ingelheim Bio Xcellence
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Patheon
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Corden Pharma
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Ajinomoto Bio- Pharma Services
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Alcami Corporation
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Piramal Pharma Solutions
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Jubilant Hollister Stier
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Cambrex Corporation
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 AMRI Global
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Thermo Fisher Scientific
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Vetter Pharma International
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 PCI Pharma Services
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 LSNE Contract Manufacturing
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us